Select Page

Leviticus Cardio is a medical device company founded in 2008 dedicated to improve the clinical outcome for patients implanted with a left ventricular assist device (LVAD) for impaired cardiac function. To date, Leviticus Cardio Ltd has raised $2 million in private venture capital and an additional $1 million in government funding. Major investors include The Trendlines Group, Israel’s foremost seed- and early-stage investment group, a consortium of acclaimed cardiovascular physicians, private investors and Israel’s Office of the Chief Scientist (OCS) in the Ministry of Economy. The Company has one approved and five pending US patents, covering wireless energy transfer into the human body and its related VAD implementations. The prevalence of heart failure can be estimated at 1–2% in the western world and the incidence approaches 5–10 per 1000 persons per year1. Congestive Heart Failure (CHF) is a very common disease in the western world, effecting around 23 million people worldwide. Of the six million people who suffer from CHF, in the US, 250,000 are in the most severe stages (NYHA Class IV) and suffer from a very poor quality of life and low chance of survival. The solution for these patients is heart transplantation (which is offered to only a small portion of patients) or a Left Ventricular Assist Device (LVAD), which is an implanted mechanical circulatory pump. According to NIH estimations, 50,000–100,000 patients in the U.S. are currently eligible for LVAD implantation. leviticus cardio diagram The LVAD is implanted in the chest and requires a power supply through a transcutaneous driveline, which connects to an external battery. This extracorporeal driveline (13.5mm to 15mm diameter) exits in the area of the patient’s abdomen, providing a portal of entry for pathogens. LVAD recipients are therefore very vulnerable to device-related infections and repeated hospitalizations. Infection remains the single most important challenge to extended VAD use. The incidence of infection reported in the HMII DT study is 0.48/pt-yr2. trendlinesThe Trendlines Group is an Israel-based innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building.]]>